Search research articles
Contact Us
Filters
Showing results (201-210 of 332) with videos related to
Page
of 34
Sort By:
Clinical Immunology (Orlando, Fla.)
|
June 7, 2008
Immunotherapy for neurological diseases
Pablo Villoslada, Beatriz Moreno, Ignacio Melero, et al.
Journal of Hepatology
|
March 8, 2013
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Bruno Sangro, Carlos Gomez-Martin, Manuel de la Mata, et al.
Oncoimmunology
|
May 31, 2019
Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells
Maria C Ochoa, Elisabeth Perez-Ruiz, Luna Minute, et al.
Cancer Immunology, Immunotherapy : CII
|
March 26, 2010
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ
Juan Dubrot, Francisca Milheiro, Carlos Alfaro, et al.
Journal for Immunotherapy of Cancer
|
March 29, 2020
Cellular cytotoxicity is a form of immunogenic cell death
Luna Minute, Alvaro Teijeira, Alfonso R Sanchez-Paulete, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 5, 2016
Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies
Arantza Azpilikueta, Jackeline Agorreta, Sara Labiano, et al.
Oncoimmunology
|
March 5, 2016
Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism
Sara Labiano, Asis Palazón, Elixabet Bolaños, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
April 22, 2006
Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication
Eduardo Huarte, Esther Larrea, Rubén Hernández-Alcoceba, et al.
Cancer Discovery
|
June 22, 2012
The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy
Asís Palazón, Iván Martínez-Forero, Alvaro Teijeira, et al.
Cancer Research
|
December 21, 2014
Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12
Ignacio Melero, Jose I Quetglas, Mercedes Reboredo, et al.
Page
of 34
Search research articles
Search
Showing results (201-210 of 332) with videos related to
Sort By:
Page
of 34
Clinical Immunology (Orlando, Fla.)
|
June 7, 2008
Immunotherapy for neurological diseases
Pablo Villoslada, Beatriz Moreno, Ignacio Melero, et al.
Journal of Hepatology
|
March 8, 2013
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Bruno Sangro, Carlos Gomez-Martin, Manuel de la Mata, et al.
Oncoimmunology
|
May 31, 2019
Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells
Maria C Ochoa, Elisabeth Perez-Ruiz, Luna Minute, et al.
Cancer Immunology, Immunotherapy : CII
|
March 26, 2010
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ
Juan Dubrot, Francisca Milheiro, Carlos Alfaro, et al.
Journal for Immunotherapy of Cancer
|
March 29, 2020
Cellular cytotoxicity is a form of immunogenic cell death
Luna Minute, Alvaro Teijeira, Alfonso R Sanchez-Paulete, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 5, 2016
Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies
Arantza Azpilikueta, Jackeline Agorreta, Sara Labiano, et al.
Oncoimmunology
|
March 5, 2016
Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism
Sara Labiano, Asis Palazón, Elixabet Bolaños, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
April 22, 2006
Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication
Eduardo Huarte, Esther Larrea, Rubén Hernández-Alcoceba, et al.
Cancer Discovery
|
June 22, 2012
The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy
Asís Palazón, Iván Martínez-Forero, Alvaro Teijeira, et al.
Cancer Research
|
December 21, 2014
Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12
Ignacio Melero, Jose I Quetglas, Mercedes Reboredo, et al.
Page
of 34